Huge Biotech Index Rebalance Means Massive Buy Orders for 5 Stocks
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
Headquartered in Parque Empresarial Can Sant Joan, Barcelona Fiscal year ends December NASDAQ: GRFS grifols.com
Grifols is a global healthcare company founded in 1909 that produces plasma-derived medicines and transfusion medicine solutions, operating in more than 110 countries with over 25,000 employees.
Its business units are:
- **Biopharma:** the largest unit, covering immunoglobulins (intravenous and subcutaneous), albumin, and Alpha-1 antitrypsin and specialty proteins such as rabies-related products. It targets immunology, neurology, pulmonology, hematology, hepatology and intensive care.
- **Diagnostic:** transfusion medicine and clinical diagnostic technologies, now being repositioned toward higher-value opportunities.
- **Bio Supplies:** biological supplies for life-science research, clinical trials and manufacturing.
Grifols runs more than 400 plasma donation centers across North America, Europe, Africa and the Middle East, and China. This includes a fast-growing public-private plasma platform in Egypt, whose plasma is EMA-approved for international use. The company holds stakes in Biotest and works with Chinese partner Shanghai RAAS on albumin distribution.
The U.S. and Canada account for the majority of revenue. Class A shares trade in Spain (IBEX-35), and non-voting Class B shares trade on the Mercado Continuo and on NASDAQ via ADRs (GRFS). Updated
The analysts at Cowen have calculated the buys and sells in the NYSE Arca Biotechnology Index based on the holdings in the First Trust Biotechnology ETF.
ThinkstockSpeculation has run hot that Swiss drugmaker Novartis A.G. (NYSE: NVS) would announced further restructuring at its investor day in London. Instead, on Friday the company announced a $5 billion share buyback…
ThinkstockThe wave of mergers and acquisitions in health care continues with two big announcements Monday. Drug maker Shire PLC (NASDAQ: SHPG) will acquire the rare disease biopharmaceutical company ViroPharma (NASDAQ: VPHM) in…
Billionaire and hedge fund manager John Paulson of Paulson & Co. and of Paulson Management is a widely followed equity hedge fund manager for whale watchers. He has made billions of dollars,…
Grifols is a global healthcare company founded in 1909 that produces plasma-derived medicines and transfusion medicine solutions, operating in more than 110 countries with over 25,000 employees.
24/7 Wall St.'s 12-month price target for GRFS is $11.85, rated Buy. The Wall Street consensus target is $10.37. GRFS price prediction →